Sunir Garg, MD
Ophthalmology · Plymouth Meeting, PANPI 1427056134
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $175,610 of the $215,702 with a category attached, or 81.4%. It is spread thinly across 23 manufacturers, the largest accounting for just 21.2%. Reporting peaked in 2023 at $80,693 and has fallen 65.7% since, to $27,694 in 2025. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 216 payments — averaging $998.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$46K
- Bausch & Lomb Americas Inc.$39K
- Apellis Pharmaceuticals, Inc.$30K
- Regeneron$29K
- Hoffmann-la Roche Limited$22K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$17K
- plus $33K from 17 others
Across 342 payments — averaging $5351.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$708K
- Apellis Pharmaceuticals, Inc.$647K
- Regeneron$355K
- Boehringer Ingelheim$62K
- Boehringer Ingelheim Pharma GmbH & Co.kg$24K
- AbbVie$16K
- plus $18K from 3 others
What the payments were for
- Consulting fees$175,61081%
- Speaking & faculty fees$16,5158%
- Travel & lodging$17,0998%
- Food & beverage$6,1683%
- Education$2710%
- Gifts$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 27 | $45,709 |
| Bausch & Lomb Americas Inc. | 64 | $38,643 |
| Apellis Pharmaceuticals, Inc. | 18 | $30,018 |
| Regeneron | 32 | $29,068 |
| Hoffmann-la Roche Limited | 5 | $21,756 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 17 | $17,144 |
| Boehringer Ingelheim International GmbH | 4 | $8,872 |
| AbbVie(2 entities) | 20 | $8,658 |
| Janssen Research & Development, LLC | 4 | $5,802 |
| Carl Zeiss Meditec, Inc. | 2 | $2,620 |
| F. Hoffmann-la Roche AG | 3 | $2,442 |
| Ocular Therapeutix, Inc. | 3 | $2,084 |
| Eyepoint US, Inc. | 5 | $1,914 |
| Regeneron Healthcare Solutions, Inc. | 1 | $470 |
| Boston Scientific | 1 | $121 |
| Genentech USA, Inc. | 1 | $87 |
| Astellas Pharma US Inc | 1 | $82 |
| Genentech, Inc. | 2 | $76 |
| Carl Zeiss Meditec AG | 2 | $39 |
| ANI Pharmaceuticals, Inc. | 1 | $35 |
| Alcon | 1 | $22 |
| NEW World Medical,inc. | 1 | $22 |
| Alimera Sciences, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$18,260
- Syfovre$15,747
- STELLARIS$13,665
- EYLEA$10,757
- VABYSMO$9,660
- XIPERE$8,864
- OZURDEX$5,903
- VYZULTA$4,766
- enVista MX60 IOL$4,649
- LOTEMAX SM$4,500
- STELLARIS ELITE$4,019
- PROLENSA$3,000
- LOTEMAX$3,000
- CRYSTALENS$3,000
- VICTUS$3,000
- ENVISTA$3,000
- ATLAS 500$2,550
- CIRRUS 6000 with AngioPlex$2,550
- CIRRUS HD-OCT$2,550
- CLARUS$2,550
How this compares
$215,702 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 271 | $12,409 |
| Bromfenac Sodium | 34 | $5,551 |
| Ketorolac Tromethamine | 59 | $1,367 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 64 | $1,326 |
| Ofloxacin | 93 | $969 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $783 |
| Atropine Sulfate | 12 | $394 |
| ErythromycinErythromycin Base | 49 | $384 |
| Timolol Maleate | 20 | $224 |
| Brimonidine Tartrate | 24 | $200 |
| Dorzolamide Hcl | 13 | $170 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 20 | $148 |
| Latanoprost | 16 | $145 |
| Prednisone | 26 | $135 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Plymouth Meeting
- Carl RegilloPlymouth Meeting$721K
- Michael KlufasPlymouth Meeting$393K
- Ajay KuriyanPlymouth Meeting$226K
- Allen HoPlymouth Meeting$225K
- Yoshihiro YonekawaPlymouth Meeting$95K
- Omesh GuptaPlymouth Meeting$85K
- Sonia MehtaPlymouth Meeting$49K
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
- Brandon AyresBala Cynwyd$929K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.